XDWH:XETRA:XETRA-Xtrackers MSCI World Health Care UCITS ETF 1C (EUR)

ETF | Others |

Last Closing

USD 50.81

Change

-0.63 (-1.22)%

Market Cap

USD 2.60B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.01 (-0.02%)

USD 420.85B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.01 (-0.08%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.03 (+0.09%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.02 (-0.07%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.09 (+0.35%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.13 (-0.29%)

USD 102.32B
8R80:XETRA Amundi Index Solutions - Amund..

+0.18 (+0.13%)

USD 102.11B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.06 (-0.12%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.50 (-0.50%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-1.84 (-0.32%)

USD 80.38B

ETFs Containing XDWH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.40% 62% D 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.40% 63% D 65% D
Trailing 12 Months  
Capital Gain 16.82% 49% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.82% 50% F 54% F
Trailing 5 Years  
Capital Gain 60.94% 78% C+ 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.94% 78% C+ 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 10.14% 70% C- 68% D+
Dividend Return 10.14% 69% C- 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.92% 65% D 72% C
Risk Adjusted Return 113.73% 99% N/A 99% N/A
Market Capitalization 2.60B 90% A- 80% B-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike